author-photo

Carole Paley

Novartis

88

Papers

1717

Citations

Citation Trend

Filter By

Papers (57) Sort By

Journal Conference Others

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

2020 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (17)
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

2017 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (32)
PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Treatment Patterns and Adherence Among Patients with Myelodysplastic Syndromes Receiving Deferasirox As Iron Chelation Therapy: A Real World Medicare Database Study

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Rapid Achievement of MR4.5 after Switching from Imatinib to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

2016 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (4)
Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia

2016 Journal of Medical Economics
Show All
- Source
- Cite
- Save
Citations (16)
Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.

2015 Journal of Emergency Medicine
Show All
- Source
- Cite
- Save
Citations (36)
Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

2015 Blood
Show All
- Source
- Cite
- Save
Citations (5)